Title: H3Africa comes of age: editorial
Authors: Mensah, GA; Peprah, EK; Sampson, UKA;
Cooper, RS
From: Cardiovascular Journal of Africa, Vol 26,
Issue 2, H3Africa Supplement for March/April
Published: 2015
Pages: S3-S5
Full text: Click here to order
»
Full text:
Click here to read online »
Full text: Click here to
read via Sabinet » (Login Required)
Abstract: With the advent of technology that
made possible large-scale sequencing and genotyping studies, it quickly became
apparent that the demographic history of our species had been recorded in the
genome and we could reconstruct our wanderings across the globe by studying DNA.
While the vast majority of genetic variation is shared among continental
populations, the most prominent finding from these early surveys of regional
populations was the substantially greater degree of heterozygosity found in
contemporary African populations.1 The ‘out of Africa’ story has long been a
central dogma in paleoanthropology, and the rich cultural and linguistic
heritage of the continent has also been well documented; yet the implications of
this phase of human history for biomedicine had never been fully appreciated.
Title: Mortality from cardiovascular diseases in sub-Saharan Africa,
1990–2013: a systematic analysis of data from the Global Burden of Disease Study
2013: cardiovascular topic
Authors: Mensah, GA; Roth, GA; Sampson, UKA;
Moran, AE; Feigin, VL; Forouzanfar, MH; Naghavi, M; Murray, CJL; for the GBD
2013 Mortality and Causes of Death collaborators
From: Cardiovascular Journal of Africa, Vol 26,
Issue 2, H3Africa Supplement for March/April
Published: 2015
Pages: S6-S10
Full text: Click here to order
»
Full text:
Click here to read online »
Full text: Click here to
read via Sabinet » (Login Required)
DOI Number: 10.5830/CVJA-2015-036
DOI Citation Reference Link:
dx.doi.org/10.5830/CVJA-2015-036
Abstract: Background: Cardiovascular disease (CVD)
has been the leading cause of death in developed countries for most of the last
century. Most CVD deaths, however, occur in low- and middle-income, developing
countries (LMICs) and there is great concern that CVD mortality and burden are
rapidly increasing in LMICs as a result of population growth, ageing and health
transitions. In sub-Saharan Africa (SSA), where all countries are part of the
LMICs, the pattern, magnitude and trends in CVD deaths remain incompletely
understood, which limits formulation of data-driven regional and national health
policies.
Objective: The aim was to estimate the number of deaths, death rates, and their
trends for CVD causes of death in SSA, by age and gender for 1990 and 2013.
Methods: Age- and gender-specific mortality rates for CVD were estimated using
the Global Burden of Disease (GBD) 2010 methods with some refinements made by
the GBD 2013 study to improve accuracy. Cause of death was estimated as in the
GBD 2010 study and updated with a verbal autopsy literature review and cause of
death ensemble modelling (CODEm) estimation for causes with sufficient
information. For all quantities reported, 95% uncertainty intervals (UIs) were
also computed.
Results: In 2013, CVD caused nearly one million deaths in SSA, constituting
38.3% of non-communicable disease deaths and 11.3% of deaths from all causes in
that region. SSA contributed 5.5% of global CVD deaths. There were more deaths
in women (512 269) than in men (445 445) and more deaths from stroke (409 840)
than ischaemic heart disease (258 939). Compared to 1990, the number of CVD
deaths in SSA increased 81% in 2013. Deaths for all component CVDs also
increased, ranging from a 7% increase in incidence of rheumatic heart disease to
a 196% increase in atrial fibrillation. The age-standardised mortality rate (per
100 000) in 1990 was 327.6 (CI: 306.2–351.7) and 330.2 (CI: 312.9–360.0) in
2013, representing only a 1% increase in more than two decades.
Conclusions: In SSA, CVDs are neither epidemic nor among the leading causes of
death. However, a significant increase in the number of deaths from CVDs has
occurred since 1990, largely as a result of population growth, ageing and
epidemiological transition. Contrary to what has been observed in other world
regions, the age-adjusted mortality rate for CVD has not declined. Another
important difference in CVD deaths in SSA is the predominance of stroke as the
leading cause of death. Attention to aggressive efforts in cardiovascular health
promotion and CVD prevention, treatment and control in both men and women are
warranted. Additionally, investments to improve directly enumerated
epidemiological data for refining the quantitation of risk exposures, death
certification and burden of disease assessment will be crucial.
Title: Familial clustering of risk factors for cardiovascular
disease among first-degree relatives of patients with chronic kidney disease in
a sub-Saharan African population: cardiovascular topic
Authors: Raji, Y; Mabayoje, O; Bello, T
From: Cardiovascular Journal of Africa, Vol 26,
Issue 2, H3Africa Supplement for March/April
Published: 2015
Pages: S11-S14
Full text: Click here to order
»
Full text:
Click here to read online »
Full text: Click here to
read via Sabinet » (Login Required)
DOI Number: 10.5830/CVJA-2015-041
DOI Citation Reference Link:
dx.doi.org/10.5830/CVJA-2015-041
Abstract: Objective: To determine the prevalence
of risk factors for cardiovascular disease (CVD) in first-degree relatives (FDRs)
of patients with chronic kidney disease (CKD) in a sub-Saharan African
population.
Methods: This was a cross-sectional survey of 460 subjects (230 FDRs of patients
with CKD and 230 healthy controls). Anthropometrics and blood pressures were
measured. Spot urine and fasting venous blood samples were obtained for
biochemical analysis.
Results: The prevalence of hypertension, diabetes mellitus, obesity and
dyslipidaemia were significantly higher in FDRs of patients with CKD compared
with the controls: 56 (24.3%) vs 29 (12.6%), p = 0.01; 20 (8.7%) vs 6 (2.6%), p
= 0.01; 40 (17.4%) vs 24 (10.4%), p = 0.03 and 171 (74.3%) vs 138 (60.0%), p =
0.01, respectively. Hypertension (OR, 1.65), dyslipidaemia (OR, 1.72) and
albuminuria (OR, 1.61) were independently associated with being a FDR of
patients with CKD.
Conclusion: In this sub-Saharan African population, risk factors for CVD were
more prevalent in the FDRs of patients with CKD than in healthy controls.
Title: Strategic investments in non-communicable diseases (NCD)
research in Africa: the GSK Africa NCD Open Lab: cardiovascular topic
Authors: Hall, MD; Dufton, AM; Katso, RM; Gatsi,
SA; Williams, PM; Strange, ME
From: Cardiovascular Journal of Africa, Vol 26,
Issue 2, H3Africa Supplement for March/April
Published: 2015
Pages: S15-S17
Full text: Click here to order
»
Full text:
Click here to read online »
Full text: Click here to
read via Sabinet » (Login Required)
DOI Number: 10.5830/CVJA-2015-042
DOI Citation Reference Link:
dx.doi.org/10.5830/CVJA-2015-042
Abstract: In March 2014, GSK announced a number
of new strategic investments in Africa. One of these included investment of up
to 25 million Pounds Sterling (£25 million) to create the world’s first R&D Open
Lab to increase understanding of non-communicable diseases (NCDs) in Africa. The
vision is to create a new global R&D effort with GSK working in partnership with
major funders, academic centres and governments to share expertise and resources
to conduct high-quality research. The Africa NCD Open Lab will see GSK
scientists collaborate with scientific research centres across Africa. An
independent advisory board of leading scientists and clinicians will provide
input to develop the strategy and selection of NCD research projects within a
dynamic and networked open-innovation environment. It is hoped that these
research projects will inform prevention and treatment strategies in the future
and will enable researchers across academia and industry to discover and develop
new medicines to address the specific needs of African patients.
Title: NHLBI perspectives on the growth of heart, lung, blood and
sleep conditions in Africa: global and domestic insights, challenges and
opportunities: cardiovacular topic Authors: Gibbons, GH; Sampson, UKA; Cook, NL; Mensah, GA
From: Cardiovascular Journal of Africa, Vol 26,
Issue 2, H3Africa Supplement for March/April
Published: 2015
Pages: S18-S20
Full text: Click here to order
»
Full text:
Click here to read online »
Full text: Click here to
read via Sabinet » (Login Required)
DOI Number: 10.5830/CVJA-2015-044
DOI Citation Reference Link:
dx.doi.org/10.5830/CVJA-2015-044
Abstract: The mission of the National Heart,
Lung, and Blood Institute (NHLBI) centres on global leadership in research,
training and education aimed at promoting the prevention and treatment of heart,
lung, blood and sleep (HLBS) disorders, and thereby enhance the pursuit of a
healthy, long and fulfilling existence by all individuals. The global horizon of
this mission reflects an appreciation of the collective destiny shared by all
humanity.
Title: Rheumatic heart disease in Africa: is there a role for
genetic studies? : review article
Authors: Mocumbi, AO
From: Cardiovascular Journal of Africa, Vol 26,
Issue 2, H3Africa Supplement for March/April
Published: 2015
Pages: S21-S26
Full text: Click here to order
»
Full text:
Click here to read online »
Full text: Click here to
read via Sabinet » (Login Required)
DOI Number: 10.5830/CVJA-2015-037
DOI Citation Reference Link:
dx.doi.org/10.5830/CVJA-2015-037
Abstract: Rheumatic heart disease (RHD)
constitutes a leading cause of premature death and incapacity in Africa, where
it is encountered in younger people, and shows a much faster and more malignant
course than that seen in Europe or North America. While it is well established
that RHD is a consequence of recurrent, untreated group A β-haemolytic
streptococcal infections (GAS), the pathogenesis is incompletely understood, and
the variation in natural history and phenotypes are not fully explained. In
Africa patients are rarely diagnosed with acute rheumatic fever (ARF). They
usually present in the late stages of RHD, with the severe and virulent forms
occurring at early ages, therefore leading to high morbidity and mortality in
young patients.
Evidence suggests that genetic factors may be involved in determining
susceptibility to ARF as well as the severity and outcomes of RHD. However, the
results of genetic studies have been inconsistent, and conflicting results have
been found in series from Africa when compared to other parts of the globe.
Genetic studies in the African context are therefore justified to understand the
genomic and epigenetic drivers of heterogeneity in individual responses to GAS
infections and progression to RHD. Platforms such as the global registry of RHD
represent an opportunity for adequately powered genome-wide association studies.
The discovery of all genetic susceptibility loci through whole-genome scanning
may provide a clinically useful genetic risk-prediction tool that will
potentially allow echocardiographic screening and secondary prophylaxis for
moderate lesions to be directed to those at higher risk, therefore reducing the
burden of the disease to the health system, the work health force and the
communities of this resource-strained continent.
Title: The burden of stroke in Africa: a glance at the present and a
glimpse into the future: review article
Authors: Owolabi, MO; Akarolo-Anthony, S;
Akinyemi, R; Arnett, D; Gebregziabher, M; Jenkins, C; Tiwari, H; Arulogun, O;
Akpalu, A; Sarfo, FS; Obiako, R; Owolabi, L; Sagoe, K; Melikam, S; Adeoye, AM;
Lackland, D; Ovbiagele, B; as members of the H3Africa Consortium
From: Cardiovascular Journal of Africa, Vol 26,
Issue 2, H3Africa Supplement for March/April
Published: 2015
Pages: S27-S38
Full text: Click here to order
»
Full text:
Click here to read online »
Full text: Click here to
read via Sabinet » (Login Required)
DOI Number: 10.5830/CVJA-2015-038
DOI Citation Reference Link:
dx.doi.org/10.5830/CVJA-2015-038
Abstract: Objective: Information on the current
burden of stroke in Africa is limited. The aim of this review was to
comprehensively examine the current and projected burden of stroke in Africa.
Methods: We systematically reviewed the available literature (PubMed and AJOL)
from January 1960 and June 2014 on stroke in Africa. Percentage change in
age-adjusted stroke incidence, mortality and disability-adjusted life years (DALYs)
for African countries between 1990 and 2010 were calculated from the Global
Burden of Diseases (GBD) model-derived figures.
Results: Community-based studies revealed an age-standardised annual stroke
incidence rate of up to 316 per 100 000 population, and age-standardised
prevalence rates of up to 981 per 100 000. Model-based estimates showed
significant mean increases in age-standardised stroke incidence. The peculiar
factors responsible for the substantial disparities in incidence velocity,
ischaemic stroke proportion, mean age and case fatality compared to high-income
countries remain unknown.
Conclusions: While the available study data and evidence are limited, the burden
of stroke in Africa appears to be increasing.
Title: Stroke genomics in people of African ancestry: charting new
paths: review article
Authors: Akinyemi, RO; Ovbiagele, B; Akpalu, A;
Jenkins, C; Sagoe, K; Owolabi, L; Sarfo, F; Obiako, R; Gebreziabher, M; Melikam,
E; Warth, S; Arulogun, O; Lackland, D; Ogunniyi, A; Tiwari, H; Kalaria, RN;
Arnett, D; Owolabi, MO; for the SIREN investigators as members of the H3Africa
Consortium
From: Cardiovascular Journal of Africa, Vol 26,
Issue 2, H3Africa Supplement for March/April
Published: 2015
Pages: S39-S49
Full text: Click here to order
»
Full text:
Click here to read online »
Full text: Click here to
read via Sabinet » (Login Required)
DOI Number: 10.5830/CVJA-2015-039
DOI Citation Reference Link:
dx.doi.org/10.5830/CVJA-2015-039
Abstract: One in six people worldwide will
experience a stroke in his/ her lifetime. While people in Africa carry a
disproportionately higher burden of poor stroke outcomes, compared to the rest
of the world, the exact contribution of genomic factors to this disparity is
unknown. Despite noteworthy research into stroke genomics, studies exploring the
genetic contribution to stroke among populations of African ancestry in the
United States are few. Furthermore, genomics data in populations living in
Africa are lacking. The wide genomic variation of African populations offers a
unique opportunity to identify genomic variants with causal relationships to
stroke across different ethnic groups. The Stroke Investigative Research and
Educational Network (SIREN), a component of the Human Health and Heredity in
Africa (H3Africa) Consortium, aims to explore genomic and environmental risk
factors for stroke in populations of African ancestry in West Africa and the
United States. In this article, we review the literature on the genomics of
stroke with particular emphasis on populations of African origin.
Title: Sickle cell disease and H3Africa: enhancing genomic research
on cardiovascular diseases in African patients: review article
Authors: Wonkam, A; Makani, J; Ofori-Aquah, S;
Nnodu, OE; Treadwell, M; Royal, C; Ohene-Frempong, K; as members of the H3Africa
Consortium
From: Cardiovascular Journal of Africa, Vol 26,
Issue 2, H3Africa Supplement for March/April
Published: 2015
Pages: S50-S55
Full text: Click here to order
»
Full text:
Click here to read online »
Full text: Click here to
read via Sabinet » (Login Required)
DOI Number: 10.5830/CVJA-2015-040
DOI Citation Reference Link:
dx.doi.org/10.5830/CVJA-2015-040
Abstract: Background: Sickle cell disease (SCD)
has a high prevalence in sub-Saharan Africa. There are several cardiovascular
phenotypes in SCD that contribute to its morbidity and mortality.
Discussion: SCD is characterised by marked clinical variability, with genetic
factors playing key modulating roles. Studies in Tanzania and Cameroon have
reported that single-nucleotide polymorphisms in BCL11A and HBS1L-MYB loci and
co-inheritance of alpha-thalassaemia impact on foetal haemoglobin levels and
clinical severity. The prevalence of overt stroke among SCD patients in Cameroon
(6.7%) and Nigeria (8.7%) suggests a higher burden than in high-income
countries. There is also some evidence of high burden of kidney disease and
pulmonary hypertension in SCD; however, the burden and genetics of these
cardiovascular conditions have seldom been investigated in Africa.
Conclusions: Several H3Africa projects are focused on cardiovascular diseases
and present major opportunities to build genome-based research on existing SCD
platforms in Africa to transform the health outcomes of patients.
Title: Endothelial dysfunction: a unifying hypothesis for the burden
of cardiovascular diseases in sub-Saharan Africa: review article
Authors: Sampson, UKA; Engelgau, MM; Peprah, EK;
Mensah, GA
From: Cardiovascular Journal of Africa, Vol 26,
Issue 2, H3Africa Supplement for March/April
Published: 2015
Pages: S56-S60
Full text: Click here to order
»
Full text:
Click here to read online »
Full text: Click here to
read via Sabinet » (Login Required)
DOI Number: 10.5830/CVJA-2015-043
DOI Citation Reference Link:
dx.doi.org/10.5830/CVJA-2015-043
Abstract: It is well established that the
leading causes of death and disability worldwide are cardiovascular diseases (CVD),
chief among which is ischaemic heart disease. However, it is also recognised
that ischaemic heart disease frequently coexists with other vascular conditions,
such as cerebrovascular, renovascular and peripheral vascular disease, thus
raising the notion of a common underlying pathobiology, albeit with differing
manifestations, dictated by the implicated vascular bed.
The understanding that common metabolic and behavioural risk factors as well as
social determinants and drivers are convergent in the development of CVD evokes
the idea that the dysfunction of a common bio-molecular platform is central to
the occurrence of these diseases. The state of endothelial activation, otherwise
known as endothelial dysfunction, occurs when reactive oxygen signalling
predominates due to an uncoupled state of endothelial nitric oxide synthase (eNOS).
This can be a physiological response to stimulation of the innate immune system
or a pathophysiological response triggered by cardiovascular disease risk
factors.
The conventional wisdom is that the endothelium plays an important role in the
initiation, progression and development of CVD and other non-communicable
diseases. Consequently, the endothelium has remarkable relevance in clinical and
public health practice as well as in health education, health promotion, and
disease- and risk-factor prevention strategies. It also presents a plausible
unifying hypothesis for the burden of CVD seen globally and in sub-Saharan
Africa. Importantly, the heterogeneity in individual responses to metabolic,
behavioural, and social drivers of CVD may stem from a complex interplay of
these drivers with genomic, epigenetic and environmental factors that underpin
eNOS uncoupling. Therefore, further biomedical research into the underlying
genetic and other mechanisms of eNOS uncoupling may enlighten and shape
strategies for addressing the burden of CVD in sub-Saharan Africa and other
regions of the world.